A Fresh Look at 10x Genomics’s (TXG) Valuation After PERIBLOOD Trial Launch and Mixed Analyst Signals

If you have been watching 10x Genomics (TXG), the latest developments likely caught your eye. This week brought a mix of cautious optimism and long-term intrigue. On one hand, fresh coverage from Piper Sandler underscored 10x Genomics’ leadership in single-cell analysis, but also warned about near-term price pressure and softer market conditions. In the same breath, 10x Genomics announced the launch of its high-profile PERIBLOOD clinical trial, an ambitious international collaboration that could transform how blood disorders are diagnosed through minimally invasive single cell RNA sequencing.

The company’s stock has been anything but steady, sliding 41% over the last year. This week alone has seen sharp moves both up and down as investors react to new research coverage, industry conferences, and product developments. Recent months have seen 10x Genomics complete a commercial restructuring, expand its technology lineup, and double down on clinical partnerships. While the short-term picture remains turbulent, the long-term potential for its single-cell and spatial transcriptomics platforms continues to be a central narrative for investors weighing risk and reward.

After this year’s big drop and a wave of new clinical momentum, is the market undervaluing 10x Genomics’ future, or is every ounce of growth already priced in?

Most Popular Narrative: 16% Undervalued

Analysts currently see 10x Genomics as undervalued, based on forecasts of earnings growth, shifting profit margins, and sector trends. Their consensus is that the company’s prospects could justify a price notably higher than today’s levels.

Recent and upcoming product launches, including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein, are expanding the range of applications and reinforcing 10x's leadership in advanced genomics tools. These developments are expected to drive both top-line growth and sustain premium pricing over time.

What is fueling analysts’ bullish outlook? There are surprising financial levers and future margin assumptions that set this fair value apart from past projections. Want to uncover the lesser-known drivers powering this valuation and see which bold forecasts underpin the numbers? The full narrative has the eye-opening details that could change how you see 10x Genomics’ future.

Result: Fair Value of $15.08 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent operating losses and tightening research budgets could quickly challenge these optimistic forecasts if market conditions worsen further.

Find out about the key risks to this 10x Genomics narrative.

Another View: SWS DCF Model Insight

Looking from a different angle, our SWS DCF model examines 10x Genomics’ future cash flows and potential growth. It neither supports nor rejects the previous view, offering a fresh lens that could reveal hidden risks or opportunities.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 10x Genomics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own 10x Genomics Narrative

If you would rather draw your own conclusions or want a different perspective, you can explore the numbers yourself and shape a unique narrative in just a few minutes. Do it your way

A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Looking for More Smart Investment Ideas?

Sharpen your next move by exploring a world of standout opportunities using the Simply Wall Street Screener. Don’t let remarkable trends and rewarding growth slip past. Take a look at these handpicked categories to spark your portfolio’s potential:

• Uncover profit potential with companies offering healthy yields by using our shortcut to dividend stocks with yields > 3%.
• Spot emerging tech innovators with game-changing neural network applications through the latest breakthroughs in AI penny stocks.
• Find overlooked gems trading below their true worth and step ahead of the crowd with undervalued stocks based on cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com